A trial looking at camizestrant for early breast cancer (CAMBRIA-2)
This trial is looking at a new drug called camizestrant for early breast cancer that has a medium to high risk of coming back.
This trial is looking at a new drug called camizestrant for early breast cancer that has a medium to high risk of coming back.
This trial is comparing stereotactic body radiotherapy to the prostate with stereotactic body radiotherapy to the prostate and lymph nodes in the pelvis.
This trial is comparing ibrutinib with, and without, treatment breaks. It is for people that have had ibrutinib for chronic lymphocytic leukaemia before.
This trial is comparing datopotamab deruxtecan and durvalumab with pembrolizumab and standard chemotherapy before surgery for breast cancer.
This study is looking at using small pieces of the DNA of bowel cancer that circulate in the blood (ctDNA) to work out whether the cancer might come back.
This trial is looking at bone marrow samples to help work out the best treatment for myeloma.
This trial is looking at whether it is possible to give pembrolizumab less often for advanced non small lung cancer.
This trial is comparing removing all the thyroid with removing only the side (lobe) that the cancer is in.